scholarly journals A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: The ‘FLARE’ instrument

2011 ◽  
Vol 71 (7) ◽  
pp. 1110-1116 ◽  
Author(s):  
Jean-Marie Berthelot ◽  
Michel De Bandt ◽  
Jacques Morel ◽  
Fatima Benatig ◽  
Arnaud Constantin ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Physician Perspectives ◽  
Flare Instrument

scholarly journals Patient and physician perspectives of hand function in a cohort of rheumatoid arthritis patients: the impact of disease activity

2016 ◽  
Vol 17 (1) ◽  
Author(s):  
Ana K. Romero-Guzmán ◽  
Víctor M. Menchaca-Tapia ◽  
Irazú Contreras-Yáñez ◽  
Virginia Pascual-Ramos
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Hand Function ◽  
Physician Perspectives ◽  
The Impact

Patient-self assessment of flare in rheumatoid arthritis: translation and reliability of the Flare instrument

2015 ◽  
Vol 35 (4) ◽  
pp. 1053-1058 ◽  
Author(s):  
Thomas Maribo ◽  
Annette de Thurah ◽  
Kristian Stengaard-Pedersen
Keyword(s):  
Rheumatoid Arthritis ◽  
Self Assessment ◽  
Flare Instrument ◽  
Patient Self Assessment

scholarly journals FRI0018 USING SELF-REPORTED OUTCOMES TO DETECT NEW-ONSET FLARE IN A REAL-WORLD STUDY OF PARTICIPANTS WITH RHEUMATOID ARTHRITIS - INTERIM RESULTS FROM THE DIGITAL TRACKING OF ARTHRITIS LONGITUDINALLY (DIGITAL) STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 580-581 ◽  
Author(s):  
V. S. Haynes ◽  
J. Curtis ◽  
F. Xie ◽  
I. Lipkovich ◽  
H. Zhao ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Test Data ◽  
Training Data ◽  
Training Dataset ◽  
Main Study ◽  
Passive Data ◽  
Digital Tracking ◽  
Flare Instrument ◽  
Daily Pain ◽  
New Onset

Background:Patients with rheumatoid arthritis (RA) experience fluctuating symptoms, increased pain, decreased function and variable quality of life; such changes often occur between visits to clinicians. Digital Tracking of Arthritis Longitudinally (DIGITAL) study2is evaluating the use of electronically captured patient-reported outcomes (ePRO) and passive data collection from a Fitbit device to identify disease worsening in a real-world study of participants (pts) with RA.Objectives:Evaluate agreement between self-reported new-onset flare and ePROs in an interim analysis from DIGITAL using a classification model.Methods:Members of the ArthritisPower registry with RA were invited to participate in DIGITAL. Pts who successfully completed a two-week Lead-in period entered the Main Study in which they wore a smartwatch and provided daily (pain and fatigue numeric rating scales (NRS)) and weekly ePROs, including the OMERACT RA Flare Questionnaire (FLARE) and PROMIS measures. This interim analysis is of ePRO data from pts who completed at least 30 days of the Main Study. A “Yes” response to the FLARE item, “Are you having a flare now?” identified flare. For modeling association between new-onset flare and ePRO, the dataset was split into training (the first 30 days of the Main Study) and test data (Day 31 and following). Within each dataset, repeated binary outcomes (Flare/No Flare) per pt were defined each week. To focus on new-onset flare, within each dataset, outcomes for patient weeks for which flare was present in the previous week were excluded.Candidate variables for the model included baseline and current FLARE score (0-50 scale) and each of its 5 items, daily pain, daily fatigue, and several PROMIS weekly instruments and their lagged values (last week or last 6 days for daily). ‘Baseline’ was calculated in non-flare weeks. Training data was used for logistic regression model selection combining clinical expertise with backward elimination. Performance of the final model was evaluated using test data.Results:The training data was composed of outcomes from 128 pts who reported 388 weekly flare assessments as no flare or onset flare over 2800 days during the first month of the Main Study. Of pts in the training dataset, 92.2% were female, 87.5% white, with mean age (SD) 52.7 (11.0) and years since RA diagnosis 10.4 (10.3); 62.5% were on a biologic. Among those in the training dataset, 58 flare outcomes occurred in 50 (39.1%) unique pts.The test data comprised outcomes from 123 pts who reported 442 weekly flare assessments as no flare or onset flare over 3366 days in which 64 flare outcomes occurred, and primarily included continued observations from pts who contributed to the training dataset.The best-performing model to classify flare in training data included the current and baseline FLARE instrument activity question (i.e. “Considering how active your rheumatoid arthritis has been, how much difficulty have you had when taking part in activities such as work, family life, social events that are typical for you during the last week”), current daily pain, and baseline daily pain average and standard deviation. In test data, this model had an area under the receiver operator curve of 0.81 (Figure). At a cut point requiring specificity to be ≥0.80, sensitivity to detect flare was 0.62 and overall accuracy was 0.78.Conclusion:New-onset flare is common among RA patients, and the FLARE instrument and daily pain scores appear effective to classify it. Evaluation of passive data as a proxy for self-reported new-onset flare is ongoing.References:[1]Bartlett SJ, et al. JRheumatol, 2017;44:1536-43.[2]Nowell WB, et al. JMIR Res Protoc, 2019;8:e14665.Disclosure of Interests:Virginia S. Haynes Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jeffrey Curtis Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Fenglong Xie: None declared, Ilya Lipkovich Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Hong Zhao: None declared, Carol L. Kannowski Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jiat-Ling Poon Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Kelly Gavigan: None declared, David Curtis: None declared, Sandra K. Nolot Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, W. Benjamin Nowell: None declared

Association of vitamin D receptor genotypes with early onset rheumatoid arthritis

2001 ◽  
Vol 28 (1) ◽  
pp. 89-93 ◽  
Author(s):  
J. R. Garcia-Lozano ◽  
M. F. Gonzalez-Escribano ◽  
A. Valenzuela ◽  
A. Garcia ◽  
A. Nunez-Roldan
Keyword(s):  
Rheumatoid Arthritis ◽  
Vitamin D ◽  
Vitamin D Receptor ◽  
Early Onset
Sign in / Sign up

Export Citation Format

Share Document